Magnitude Biosciences appoints new CEO

Fozia Saleem

Magnitude Biosciences Limited, a Durham University spin-out based at NETPark in Sedgefield, has appointed a new CEO, Fozia Saleem.

Magnitude Biosciences is one of the world’s leading commercial providers of services for determining the effects of compounds on ageing, longevity, neurodegeneration and reproductive health. The company spun out of Durham University in 2018 with support from Northern Accelerator.

Fozia joins from Broughton Life Sciences, a global life sciences consultancy, where she was Director of Product Development Services and a core member of the senior leadership team. She has a PhD in molecular physiology from the University of Edinburgh and started her career in industry at GlaxoSmithKline. Fozia subsequently worked for British American Tobacco and Nicoventures Holdings where she had a wide range of responsibilities, including product development, project delivery and revenue growth.

David Weinkove, co-founder of Magnitude Biosciences will continue as CSO. As CEO and Chief Scientific Officer (CSO), David has grown the business from an academic lab in Durham University to a company with annual revenue of nearly £0.5m.

Magnitude Biosciences’ Chair, Sally Waterman, commented “I am thrilled to welcome Fozia to the Company to lead the next stage of its growth. There is significant interest and investment in companies developing products to help us live longer and healthier lives. Magnitude Biosciences offers research services to enable companies to rapidly identify the most promising compounds and is poised to benefit from the growth in this area.

“David is internationally renowned for his expertise in C. elegans research and his leadership of the scientific team and ability to design experiments to meet the often-challenging needs of companies will continue to drive growth of the business.”

Read more on Magnitude Biosciences’ website here.